News - TOSP

Find Out The Latest

Keep in touch with news and developments from The Oxford Science Park and its occupiers here.

You can also follow us on LinkedIn

Moa and Certis Belchim sign strategic collaboration deal

08 Jan 2026

Netherlands-based company becomes Moa's third major commercial partner in 18 months. Moa Technology and Certis Belchim have announced a new strategic collaboration, marking a significant step forward in the development of next-generation herbicides for global agriculture. This partnership brings together Moa Technology’s breakthrough discovery platforms, which have identified over 80 new herbicidal modes of action in the past three... Read more

Dark Blue Therapeutics acquired by Amgen to bolster oncology pipeline

06 Jan 2026

Dark BlueTherapeutics, located at The Oxford Science Park, has been acquired by global biopharmaceutical company Amgen, in a transaction valued at up to $840 million. Based on unique academic insights from the University of Oxford, the team at Dark Blue Therapeutics are developing a small molecule that targets and degrades two proteins that drive specific types of acute myeloid leukemia, a fast-growing blood cancer. Dark Blue says its... Read more

Pumping station tops out in time for Christmas

17 Dec 2025

The Oxford Science Park, together with Thames Water and Morgan Sindall, have celebrated the topping out of its new pumping station enclosure ahead of the Christmas break. The project forms part of a three-year collaboration between The Oxford Science Park and Thames Water to design and deliver the relocation of an existing pumping station that is more than 40 years old. While modest in scale, the scheme has presented significant technical... Read more

Oxford BioTherapeutics announces strategic collaboration with GSK

12 Dec 2025

Oxford BioTherapeutics (OBT), a clinical stage oncology company based at The Oxford Science Park, today announced a multi-year, multi-target strategic collaboration with GSK to discover novel potentially first-in-class antibody-based therapeutics for the treatment of cancer. OBT's recently enhanced proprietary OGAP®-Verify discovery platform enables highly sensitive identification of oncology targets with improved attributes for drug... Read more

EIT-funded Generative Biology Doctoral Training Programme launches at Oxford University

10 Dec 2025

The University of Oxford, in partnership with the Ellison Institute of Technology (EIT), plans to launch the Generative Biology Doctoral Training Programme (DTP) - a four-year DPhil designed to allow the next generation of researchers to explore how to synthesize the DNA sequences of organisms to program and engineer biology. Fully funded by EIT, the programme will be hosted by Oxford’s Department of Chemistry and involves academics from... Read more